ROCK2 inhibitor
Belumosudil
Brand names: Rezurock
Adult dose
Dose: 200mg PO OD
Route: Oral
Frequency: OD
Clinical pearls
- Chronic graft-versus-host disease after ≥2 lines of systemic therapy
- NICE TA evaluation; BSH HSCT GvHD guidelines
- Specialist post-HSCT clinic
Contraindications
- Severe hepatic impairment
- Pregnancy
- Hypersensitivity
Side effects
- Infections
- Asthenia
- Nausea
- Diarrhoea
- Headache
- Hepatotoxicity
- Hypertension
- Pulmonary effects
Interactions
- Strong CYP3A4 inhibitors/inducers
- Acid-suppressants (separate)
Monitoring
- LFTs
- Symptoms
- BP
- Infections
Reference: BNF; NICE TA evaluation; BSH; SmPC; https://bnf.nice.org.uk/drugs/belumosudil/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO